1.0Advant Altanahttps://backup.altanalaw.com/enBIOTECH - Advant Altanarich600338<blockquote class="wp-embedded-content" data-secret="LcfkxGK5Gn"><a href="https://backup.altanalaw.com/en/medias/biotech">BIOTECH</a></blockquote><iframe sandbox="allow-scripts" security="restricted" src="https://backup.altanalaw.com/en/medias/biotech/embed#?secret=LcfkxGK5Gn" width="600" height="338" title="“BIOTECH” — Advant Altana" data-secret="LcfkxGK5Gn" frameborder="0" marginwidth="0" marginheight="0" scrolling="no" class="wp-embedded-content"></iframe><script type="text/javascript">
/* <![CDATA[ */
/*! This file is auto-generated */
!function(d,l){"use strict";l.querySelector&&d.addEventListener&&"undefined"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!/[^a-zA-Z0-9]/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret="'+t.secret+'"]'),o=l.querySelectorAll('blockquote[data-secret="'+t.secret+'"]'),c=new RegExp("^https?:$","i"),i=0;i<o.length;i++)o[i].style.display="none";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute("style"),"height"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):"link"===t.message&&(r=new URL(s.getAttribute("src")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener("message",d.wp.receiveEmbedMessage,!1),l.addEventListener("DOMContentLoaded",function(){for(var e,t,s=l.querySelectorAll("iframe.wp-embedded-content"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute("data-secret"))||(t=Math.random().toString(36).substring(2,12),e.src+="#?secret="+t,e.setAttribute("data-secret",t)),e.contentWindow.postMessage({message:"ready",secret:t},"*")},!1)))}(window,document);
/* ]]> */
</script>
On 23 November 2016, Jean-Nicolas Soret attended the annual reception organized by France Biotech, the French association dedicated to the promotion of this rapidly developing sector. ALTANA is active in this area, as counsel to both biotech and medtech companies as well as CROs in their various projects. As previously reported, ALTANA advised ONXEO in both […]